Serum tenascin-C predicts resistance to steroid combination therapy in high-risk Kawasaki disease: a multicenter prospective cohort study

被引:8
作者
Yoshikane, Yukako [1 ]
Okuma, Yoshiaki [2 ]
Miyamoto, Tatsuki [1 ]
Hashimoto, Junichi [1 ]
Fukazawa, Ryuji [3 ]
Kato, Taichi [4 ]
Takeda, Atsuhito [5 ]
Suda, Kenji [6 ]
Matsushita, Takeji [2 ]
Hiroe, Michiaki [7 ]
Imanaka-Yoshida, Kyoko [8 ]
机构
[1] Fukuoka Univ, Fac Med, Dept Pediat, 7-45-1 Nanakuma, Jonan, Fukuoka 8140133, Japan
[2] Natl Ctr Global Hlth & Med, Dept Pediat, Tokyo, Japan
[3] Nippon Med Sch, Dept Pediat, Tokyo, Japan
[4] Nagoya Univ, Dev Pediat, Grad Sch Med, Nagoya, Aichi, Japan
[5] Hokkaido Univ, Dept Pediat, Grad Sch Med, Sapporo, Hokkaido, Japan
[6] Kurume Univ, Dept Pediat & Child Hlth, Sch Med, Fukuoka, Japan
[7] Natl Ctr Global Hlth & Med, Dept Cardiol, Tokyo, Japan
[8] Mie Univ, Dept Pathol & Matrix Biol, Grad Sch Med, Tsu, Mie, Japan
关键词
Kawasaki disease; Tenascin C; Biomarkers; Prospective study; Kobayashi score; High-risk; Resistant; IVIG; Steroids; Prednisolone; INTRAVENOUS GAMMA-GLOBULIN; IMMUNOGLOBULIN RESISTANCE; RETREATMENT; LESIONS; SCORE;
D O I
10.1186/s12969-021-00562-w
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
BackgroundTenascin-C (TN-C) is an extracellular matrix glycoprotein related to tissue inflammation. Our previous retrospective study conducted in 2016 revealed that the serum tenascin-C level was higher in patients with Kawasaki disease (KD) who were resistant to intravenous immunoglobulin (IVIG) and developed coronary artery lesions (CALs). The present study is a prospective cohort study to assess if the serum level of tenascin-C could be used as a novel biomarker to predict the risk of resistance to initial treatment for high-risk patients.MethodsA total of 380 KD patients were registered and provided serum samples for tenascin-C measurement before commencing their initial treatment. Patients who did not meet the inclusion criteria were excluded from analysis; of the 181 remaining subjects, there were 144 low-risk patients (Kobayashi score: <= 4 points) and 37 high-risk patients (Kobayashi score: >= 5 points). The initial treatments for low-risk patients and high-risk patients were conventional therapy (IVIG with aspirin) and prednisolone combination therapy, respectively. The patient clinical and laboratory data, including the serum tenascin-C level, were compared between initial treatment responders and non-responders.ResultsIn the low-risk patients, there was no significant difference in the median levels of serum tenascin-C between the initial therapy responders and non-responders. However, in the high-risk patients, the median serum tenascin-C level in initial therapy non-responders was significantly higher than that in initial therapy responders (175.8ng/ml vs 117.6ng/ml).ConclusionsSerum tenascin-C could be a biomarker for predicting the risk of high-risk patients being non-responsive to steroid combination therapy.Trial registrationThis study was a prospective cohort study. It was approved by the ethics committee of each institute and performed in accordance with the Declaration of Helsinki.
引用
收藏
页数:9
相关论文
共 40 条
  • [1] [Anonymous], 2012, PEDIAT CARDIOL CARDI
  • [2] Revision of diagnostic guidelines for Kawasaki disease (the 5th revised edition)
    Ayusawa, M
    Sonobe, T
    Uemura, S
    Ogawa, S
    Nakamura, Y
    Kiyosawa, N
    Ishii, M
    Harada, K
    [J]. PEDIATRICS INTERNATIONAL, 2005, 47 (02) : 232 - 234
  • [3] Kawasaki syndrome
    Burns, JC
    Glodé, MP
    [J]. LANCET, 2004, 364 (9433) : 533 - 544
  • [4] Intravenous gamma-globulin treatment and retreatment in Kawasaki disease
    Burns, JC
    Capparelli, EV
    Brown, JA
    Newburger, JW
    Glode, MP
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1998, 17 (12) : 1144 - 1148
  • [5] Predicting IVIG resistance in UK Kawasaki disease
    Davies, Sarah
    Sutton, Natalina
    Blackstock, Sarah
    Gormley, Stuart
    Hoggart, Clive J.
    Levin, Michael
    Herberg, Jethro A.
    [J]. ARCHIVES OF DISEASE IN CHILDHOOD, 2015, 100 (04) : 366 - 368
  • [6] Immunoglobulin failure and retreatment in Kawasaki disease
    Durongpisitkul, K
    Soongswang, J
    Laohaprasitiporn, D
    Nana, A
    Prachuabmoh, C
    Kangkagate, C
    [J]. PEDIATRIC CARDIOLOGY, 2003, 24 (02) : 145 - 148
  • [7] The Clinical Utility and Safety of a New Strategy for the Treatment of Refractory Kawasaki Disease
    Ebato, Takasuke
    Ogata, Shohei
    Ogihara, Yoshihito
    Fujimoto, Mayu
    Kitagawa, Atsushi
    Takanashi, Manabu
    Ishii, Masahiro
    [J]. JOURNAL OF PEDIATRICS, 2017, 191 : 140 - 144
  • [8] Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease
    Egami, Kimiyasu
    Muta, Hiromi
    Ishii, Masahiro
    Suda, Kenji
    Sugahara, Yoko
    Iemura, Motofumi
    Matsuishi, Toyojiro
    [J]. JOURNAL OF PEDIATRICS, 2006, 149 (02) : 237 - 240
  • [9] Fujimoto Naoki, 2009, J Card Fail, V15, P898, DOI 10.1016/j.cardfail.2009.06.443
  • [10] FURUSHO K, 1984, LANCET, V2, P1055